Health Care & Hospitals

Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease

Thu, 29 Oct 2026 02:00:00 +0000

TOKYO, Oct. 28, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical...

The Inner Circle acknowledges David R. Neff, DO as a Pinnacle Lifetime Member

Wed, 28 Oct 2026 23:50:00 +0000

EAST LANSING, Mich., Oct. 28, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, David R. Neff, DO is acknowledged as a Pinnacle Lifetime Member for his contributions in Medicine, Education, and Research. David R. Neff, DO, has built a distinguished career spanning more than...

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

Wed, 28 Oct 2026 23:40:00 +0000

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and...

The Inner Circle acknowledges Dr. Michael M. Pennock, MD, MBiot, DABR, as a Pinnacle Lifetime Member

Wed, 28 Oct 2026 23:19:00 +0000

BEAVER, Pa., Oct. 28, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Michael M. Pennock, MD, MBiot, DABR is recognized as a Pinnacle Lifetime Member for his contributions to Radiation Oncology. Dr. Michael M. Pennock, a board-certified, dedicated radiation oncologist with...

Gameday Men's Health Sets the Safety Standard as New Federal Policy Expands Peptide Access

Wed, 28 Oct 2026 22:16:00 +0000

Peptides, prescribed the right way: licensed clinicians, licensed pharmacies, no research chemicals CARLSBAD, Calif., Oct. 28, 2026 /PRNewswire/ -- Gameday Men's Health, the leader in men's health and wellness with more than 430 clinics across the US and Canada offering testosterone...

HOPE CHARITIES ENDORSES H.R. 10549 TO PUT PATIENTS BACK IN THE DRIVER'S SEAT FOR SPECIALTY CARE

Wed, 28 Oct 2026 22:11:00 +0000

Patients Choice in Specialty Pharmacy Act would end plan steering toward insurer- and PBM-owned specialty pharmacies while letting patients keep the pharmacy they have PRAIRIEVILLE, La., Oct. 28, 2026 /PRNewswire/ -- Hope Charities today announced its support for H.R. 10549, the Patients...

WHEN SOMEONE YOU KNOW IS DIAGNOSED WITH BREAST CANCER, KNOWING HER RADIATION OPTIONS CAN MAKE A DIFFERENCE

Wed, 28 Oct 2026 21:38:00 +0000

SOMERSET, N.J., Oct. 28, 2026 /PRNewswire/ -- Most people know to encourage the women in their lives to stay current with breast cancer screening. But when a friend, partner, mother or colleague is diagnosed, a different question often follows: What treatment options should she ask about?...

John Couris, Jennifer Crabtree and Three Florida Health Sciences Center Board Members Named to Florida Trend's 2026 "Florida 500"

Wed, 28 Oct 2026 21:33:00 +0000

Five leaders recognized among Florida's most influential, reflecting a depth and breadth of leadership spanning health care, research, business and civic life while expanding access to academic medicine, accelerating innovation and fueling economic growth across Florida. TAMPA, Fla., Oct....

HERVolution Publishes Foundational Data Demonstrating Rationally Engineered HERV-K Antigens Can Break Immune Tolerance and Train Immune Cells to Target Cancer Cells

Wed, 28 Oct 2026 20:37:00 +0000

Peer-reviewed study describes the rationally engineered envelope modification underpinning HERVolution's lead program, IPT-001, and detects HERV-K expression across the majority of 43 cancer types in 1,353 patients COPENHAGEN, Denmark and NEW YORK, Oct. 28, 2026 /PRNewswire/ --...

The Cigna Group Declares Quarterly Dividend

Wed, 28 Oct 2026 20:30:00 +0000

BLOOMFIELD, Conn., Oct. 28, 2026 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE: CI) today declared a cash dividend of $1.56 per share of its common stock, payable on December 17, 2026, to shareholders of record as of the close of business on December 3, 2026. About The...

AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS

Wed, 28 Oct 2026 20:30:00 +0000

THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with...

TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

Wed, 28 Oct 2026 20:30:00 +0000

Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment TransCode will evaluate strategic alternatives including licensing arrangements, development partnerships and other strategic transactions BOSTON, Oct. 28,...

Encompass Health reports results for third quarter 2026

Wed, 28 Oct 2026 20:20:00 +0000

Increases full-year guidance BIRMINGHAM, Ala., Oct. 28, 2026 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September...

Purple Innovation to Report Third Quarter 2026 Results on November 4, 2026

Wed, 28 Oct 2026 20:15:00 +0000

LEHI, Utah, Oct. 28, 2026 /PRNewswire/ -- Purple Innovation, Inc. (NASDAQ: PRPL) ("Purple"), a comfort innovation company whose mattresses promise to give you "less pain, better sleep," will report third quarter 2026 financial results on Wednesday, November 4, 2026 at approximately 4:05 p....

SERVICE CORPORATION INTERNATIONAL ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS AND UPDATES FOURTH QUARTER OUTLOOK

Wed, 28 Oct 2026 20:15:00 +0000

Conference call on Thursday, October 29, 2026, at 8:00 a.m. Central Time. HOUSTON, Oct. 28, 2026 /PRNewswire/ -- Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today reported results for the third quarter of 2026....

Euvita Health Launches Nationwide Whole-Health and Longevity Platform

Wed, 28 Oct 2026 20:14:00 +0000

The new healthcare company builds on strategic acquisitions and partnerships to integrate functional medicine, advanced biomarker analysis, nutrition, sleep, fitness, supplements and personalized medical care into one coordinated platform. WEST PALM BEACH, Fla., Oct. 28, 2026 /PRNewswire/...

Artivion to Participate in Upcoming Investor Conferences

Wed, 28 Oct 2026 20:10:00 +0000

ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2026...

Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027

Wed, 28 Oct 2026 20:07:00 +0000

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643...

Bausch Health Announces US$50 Million Share Repurchase Program

Wed, 28 Oct 2026 20:06:00 +0000

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price...

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Wed, 28 Oct 2026 20:05:00 +0000

-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019...